

COST-EFFECTIVENESS OF AN ANTIBACTERIAL ENVELOPE

A PRE-SPECIFIED ANALYSIS OF THE WRAP-IT TRIAL



CIED INFECTIONS

Outcomes, Costs Per Infection

- >3X mortality risk at 1 year
- Suppressed quality of life for 6 months
- \$55,000 avg hospital cost to treat

Envelope Effectiveness

- 40% reduction of major CIED infections with TYRX



ANALYSIS METHODS

Model

- Value defined as dollars spent to achieve health outcome
- Integrated payer-provider perspective
- Decision tree based on costs and outcomes from the WRAP-IT Trial



ECONOMIC RESULTS

Cost-Effectiveness Ratio

- \$112,000 per quality adjusted life-year

Willingness-to-pay Threshold

- \$150,000 per QALY, aligned with ACC/AHA practice guideline recommendations



CONCLUSION

The TYRX absorbable antibacterial envelope was associated with a cost-effectiveness ratio below contemporary benchmarks in the WRAP-IT patient population, suggesting that the envelope provides value for the US healthcare system.